Baird: Maintaining the Crinetics Pharmaceuticals (CRNX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $52.00 to $62.00.
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and BioMarin Pharmaceutical (BMRN)
Novavax Analyst Ratings
Crinetics Pharmaceuticals Analyst Ratings
Novavax Inc.: B. Riley increases target price from $11 to $29
Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating
Crinetics Pharmaceuticals Inc: Baird raises price target from $52 to $62
Dyne Therapeutics Inc: J.P. Morgan raises price target from $25 to $39
RBC Capital Sticks to Its Hold Rating for PTC Therapeutics (PTCT)
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Promising Atumelnant Data for CAH
Hold Rating on PTC Therapeutics Amid Regulatory Uncertainty for Translarna
Komo: Maintaining the United Therapeutics (UTHR.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $280.00 to $300.00.
United Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $300
PTC Therapeutics Analyst Ratings
Goldman Sachs: Maintains PTC Therapeutics (PTCT.US) rating, adjusted from sell to sell rating, and adjusted target price from $18.00 to $32.00.
Chardan Capital: Maintaining the Dyne Therapeutics (DYN.US) rating, adjusted from buy to buy rating, and adjusted the target price from $31.00 to $42.00.
Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Conmed (CNMD) and PTC Therapeutics (PTCT)